Fisher & Paykel Healthcare Corporation Limited · NZX:FPH
Fisher & Paykel Healthcare — Shareholder Meeting (2018)
34 slides from Fisher & Paykel Healthcare's shareholder meeting presentation, 2018
Slide 1: Annual Shareholders' Meeting
Annual Share! Fisher & Paykel HEALTHCARE
Slide 2: Tony Carter, Chairman
Tony Carter, Chairman > Fisher &Paykel HEALTHCARE
Slide 3: Your Board
Your Board Lewis Gradon Michael Daniell Pip Greenwood Geraldine McBride Arthur Morris Donal O’Dwyer Scott St John Fisheré.Paykel HEALTHCARE
Slide 4: Agenda
Agenda * Chair's Address * Managing Director and Chief Executive Officer’s Review * Financial Statements * Resolutions * Voting * General Questions Fisher & Paykel HEALTHCARE
Slide 5: FY2018 Financial Results
FY2018 Financial Results Record Operating Revenue nz$980m Record Net Profit after Tax Nz$1 90m HEALTHCARE
Slide 6: Product Group Revenue
Product Group Revenue Hospital OF OPERATING REVENUE NZ$572M Homecare Distributed and Other OF OPERATING REVENUE
Slide 7: Responding to healthcare needs
Responding to healthcare needs * Majority of healthcare costs incurred through labour * Our products are easy to use and can reduce likelihood of escalation: - Improving patient outcomes - Reducing costs to healthcare providers Fisher &Paykel HEALTHCARE
Slide 8: Fisher & Paykel
Fisher & Paykel HEALTHCARE
Slide 9: Your Board
Your Board Lewis Gradon Michael Daniell Pip Greenwood Geraldine McBride Arthur Morris Donal O’Dwyer Scott St John Fisheré.Paykel HEALTHCARE
Slide 10: Tony Carter, Chairman
Tony Carter, Chairman > Fisher &Paykel HEALTHCARE
Slide 11: Lewis Gradon, Managing Director and CEO
Lewis Gradon, Managing Director and CEO Fisheré.Paykel HEALTHCARE
Slide 12: Fisher & Paykel Healthcare - a global leader
Fisher & Paykel Healthcare - a global leader Medical technology business with leading positions in respiratory care and obstructive sleep apnea Global reach into hospital and homecare (99% of sales and 1,800 people outside NZ) 45+ years’ experience changing clinical practice to improve clinical outc
Slide 13: Fisher & Paykel
Fisher & Paykel HEALTHCARE
Slide 14: Slide 14
Slide 15: Clinical research
Clinical research Optiflow Junior & Airvo - PARIS study myAirvo - Storgaard study World’s largest randomised control tri High Flow (NHF) therapy Significantly lower rates of escalati infants on NHF New England Journal of Medicine Primary outcome a significant reduction i exacerbation rate with NHF A
Slide 16: Slide 16
Slide 17: Slide 17
Slide 18: FY2019 Outlook
FY2019 Outlook Full Year Expect NZD:USD exchange rate of ~O.67 for the balance of the year Operating Revenue Approximately NZ$1.07 billion Net Profit after Tax Approximately NZ$215 million First Half Expect at current exchange rates Operating Revenue Approximately NZ$510 million Net Profit after Tax
Slide 19: Tony Barclay
Tony Barclay ; Fisher &Paykel HEALTHCARE
Slide 20: Lewis Gradon, Managing Director and CEO
Lewis Gradon, Managing Director and CEO Fisheré.Paykel HEALTHCARE
Slide 21: Tony Carter, Chairman
Tony Carter, Chairman > Fisher &Paykel HEALTHCARE
Slide 22: Arthur Morris
Arthur Morris Fisher &Paykel HEALTHCARE
Slide 23: Financial Statements
Financial Statements * Opportunity for shareholders to ask any questions specifically on the financial statements, the auditor’s report or the company’s 2018 annual report. * There will be an opportunity to ask any general questions once all items on the agenda have been considered. Fisher & Paykel
Slide 24: Resolutions
Resolutions * Re-election of Directors - Scott St John - Michael Daniell « Auditor’s Remuneration * Issue of Performance Share Rights * Issue of Options Fisher & Paykel HEALTHCARE
Slide 25: Resolution 1: Re-election of Scott St John
Resolution 1: Re-election of Scott St John That Scott St John, who retires by rotation and, being eligible, offers himself for re-election, be re-elected as a director of the Company. Fisher &Paykel HEALTHCARE
Slide 26: Resolution 2: Re-election of Michael Daniell
Resolution 2: Re-election of Michael Daniell That Michael Daniell, who retires by rotation and, being eligible, offers himself for re-election, be re-elected as a director of the Company. Fisher &Paykel HEALTHCARE
Slide 27: Resolution 3: Auditor's Remuneration
Resolution 3: Auditor’s Remuneration That the Directors be authorised to fix the fees and expenses of PwC as the Company’s auditor. Fisher & Paykel HEALTHCARE
Slide 28: Resolution 4: Issue of Performance Share Rights
Resolution 4: Issue of Performance Share Rights That approval be given for the issue of up to 50,000 performance share rights under the Fisher & Paykel Healthcare Performance Share Rights Plan to Lewis Gradon, Managing Director and Chief Executive Officer of the Company. Fisher & Paykel HEALTHCARE
Slide 29: Resolution 5: Issue of Options
Resolution 5: Issue of Options That approval be given for the issue of up to 150,000 options under the Fisher & Paykel Healthcare 2003 Share Option Plan to Lewis Gradon, Managing Director and Chief Executive wr Officer of the Company. \\ A si Www Fisher &Paykel HEALTHCARE
Slide 30: Voting
Voting yo In respect of each resolution, please tick the “for”, “against” or “abstain” box. Once you have completed your voting, please hand your paper to a representative from Link Market Services. Please raise your hand if you require a pen. Results will be announced to NZX and ASX as soon as they
Slide 31: Questions?
Questions? Fisher & Paykel HEALTHCARE
Slide 32: Annual Shareholders' Meeting
Annual Share! Fisher & Paykel HEALTHCARE
Slide 33: Proxies
Proxies Total votes Resolution For % Against Abstain cast 1: Re-election of Scott St John 371,879,801 99.0 2,698,774 375,801,131 121,711 2: Re-election of Mike Daniell 359,393,924 95.6 15,209,484 375,812,517 110,325 3: Authorise Directors to fix fees and expenses of auditor 374,020,086 99.5 552,323
Slide 34: Annual Shareholders' Meeting
Annual Share! Fisher & Paykel HEALTHCARE
Fisher & Paykel Healthcare — Shareholder Meeting (2018) on 6ix